NPPB and chronic obstructive pulmonary disease: PH therapy was significantly and independently associated with reduced risk of death or transplant in patients with PVR > 5 WU (HR 0.29, 95% CI 0.10–0.81, p = 0.02) and patients with PVR > 5 WU and mPAP > 40 mmHg (HR 0.11, 95% CI, 0.17–0.74, p = 0.02), even when accounting for other markers of disease severity (GOLD stage, DLCO, 6MWD, O2 requirement, BNP) and COPD treatment (triple inhaled therapy).